PMID: 2886325Jul 1, 1987Paper

Drug-antacid interactions: assessment of clinical importance

Drug Intelligence & Clinical Pharmacy
P F D'Arcy, J C McElnay


Antacids and adsorbents are commonly used preparations that are generally considered to be pharmacologically inert and free from adverse effects. They may, however, interact with a diverse range of primary drugs and the sequelae can be disadvantageous to the efficacy of the primary medication. Many such reports in the literature are based on animal experiments, or on single-dose studies in healthy subjects. Some reports are anecdotal and are unconfirmed; others are based solely on in vitro evidence. Potentially important interactions have been suggested for a relatively small group of drugs: tetracyclines, phenytoin, digoxin, chloroquine, cimetidine, quinidine, nonsteroidal antiinflammatory drugs, and beta-blocking agents. The evidence for these has been critically evaluated, as well as for antacid-anticoagulant and antacid-nitrofurantoin interactions that have been wrongly emphasized in the literature. The majority of literature reports on interactions with antacids have been overemphasized; only ferrous sulfate-, isoniazid-, and tetracycline-antacid interactions fall into a category I importance (scale I-III of descending importance). This category is for those interactions with good evidence of actual or potential importance...Continue Reading


Dec 1, 1975·Journal of Pharmaceutical Sciences·M GibaldiG Levy
Feb 1, 1977·Journal of Pharmaceutical Sciences·S A Khalil
Jun 1, 1979·Clinical Pharmacology and Therapeutics·V F Naggar, S A Khalil
Aug 1, 1977·Journal of Pharmaceutical Sciences·L D Bighley, R J Spivey
Feb 24, 1979·Lancet·G BodemarA Walan
Jan 31, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·H Poiger, C Schlatter
Jul 1, 1975·Journal of Clinical Pharmacology·W E Thornton, B J Pray
Jul 1, 1977·Clinical Pharmacokinetics·A Hurwitz
Jul 1, 1979·Archives of Neurology·D J ChapronD C Hohnadel
Oct 15, 1979·Experientia·J C McElnayP S Collier
Dec 1, 1977·Journal of Pharmacokinetics and Biopharmaceutics·E MartinS Riegelman
Dec 1, 1977·Journal of Pharmacokinetics and Biopharmaceutics·R K NayakN H Reavey-Cantwell
Aug 1, 1978·British Journal of Clinical Pharmacology·L S O'BrienA M Breckenridge
Aug 1, 1978·British Journal of Clinical Pharmacology·V K KulshresthaA Richens
Nov 1, 1978·Clinical Pharmacology and Therapeutics·D J GreenblattR I Shader
Oct 21, 1978·British Medical Journal·J Cooke, J A Smith
Feb 1, 1976·Clinical Pharmacology and Therapeutics·D J GreenblattJ Koch-Weser
Jan 1, 1975·Clinical Toxicology·J W Hayden, E G Comstock
Mar 1, 1977·Clinical Pharmacology and Therapeutics·T M LuddenJ L McNay
Nov 4, 1976·The New England Journal of Medicine·D D Brown, R P Juhl
Dec 1, 1976·Journal of Pharmaceutical Sciences·E C Newman, C W Frank
Dec 1, 1976·Journal of Pharmaceutical Sciences·L J StoelC W Frank
Oct 1, 1986·Drug Intelligence & Clinical Pharmacy·D W ShellyJ Perrin
Feb 1, 1985·Journal of the American Academy of Dermatology·J J Leyden
Aug 1, 1985·British Journal of Clinical Pharmacology·P J NeuvonenO Penttilä
Sep 1, 1985·British Journal of Clinical Pharmacology·H L SmartM J Langman
Mar 1, 1973·Clinical Pharmacology and Therapeutics·J J Ambre, L J Fischer
Dec 1, 1974·The Journal of Pharmacy and Pharmacology·S A Khalil
Oct 12, 1968·The Medical Journal of Australia·B G Lucas
Dec 6, 1969·Lancet·L F Prescott
Oct 12, 1968·The Medical Journal of Australia·P J Landy
Sep 1, 1971·Clinical Pharmacology and Therapeutics·W H BarrL Garrettson
Nov 1, 1969·Annals of Internal Medicine·R E GerhardtJ J Morris
Oct 31, 1970·British Medical Journal·J H TyrerW D Hooper
Nov 28, 1970·British Medical Journal·P J NeuvonenK Björksten
May 1, 1971·European Journal of Clinical Investigation·L Rivera-CalimlimJ R Bianchine
May 1, 1971·Clinical Pharmacology and Therapeutics·D S RobinsonJ J McCormack
Jan 1, 1968·Chemotherapy·M Schach von Wittenau
Oct 1, 1968·The American Journal of Physiology·K Thomsen, M Schou
Sep 21, 1968·The Medical Journal of Australia·M J EadieJ H Tyrer
Sep 14, 1968·The Medical Journal of Australia·J Balla
Aug 17, 1968·The Medical Journal of Australia·L Rail
Sep 1, 1981·Journal of Pharmaceutical Sciences·A J BucciL S Shenouda
Mar 1, 1984·The Journal of Pharmacy and Pharmacology·M Riaz, N Pilpel
Jul 1, 1983·Clinical Pharmacokinetics·R K VerbeeckG R Loewen

❮ Previous
Next ❯


Oct 1, 1989·DICP : the Annals of Pharmacotherapy·A Hurwitz, C A Carter
Nov 9, 2000·Clinical Pharmacokinetics·D A FlockhartS K Mahal
Sep 24, 1999·Alimentary Pharmacology & Therapeutics·T J Humphries, G J Merritt
Aug 29, 2001·Clinical Pharmacokinetics·M R Marino, N N Vachharajani
Mar 1, 1991·British Journal of Clinical Pharmacology·P J Neuvonen
Jan 1, 1988·European Journal of Clinical Pharmacology·P J Neuvonen, K T Kivistö
Jan 1, 1996·American Journal of Physical Medicine & Rehabilitation·S E BravermanP V Belandres
Feb 8, 2007·Pharmazie in unserer Zeit·Tanja WegatWalter E Müller
Sep 16, 2003·Journal of Clinical Pharmacology·Aryeh HurwitzMatthew S Mayo
Sep 13, 2001·Alimentary Pharmacology & Therapeutics·C L Sheen, D G Colin-Jones
Jul 25, 2021·International Journal of Molecular Sciences·Ellen Niederberger, Michael J Parnham

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
A G JohnsonR O Day
Drug Safety : an International Journal of Medical Toxicology and Drug Experience
D C Sadowski
Journal of the American Geriatrics Society
M A Jenike
© 2021 Meta ULC. All rights reserved